Healthcare Industry News’ Post

Drug Discovery Services Market Latest Statistics 2024 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dtcN7Umn The size of global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028 Companies From the Market Enanta Pharmaceuticals NGM Biopharmaceuticals Biocytogen XtalPi Inc. NanoCellect Biomedical, Inc.    X-Chem, Inc. FUJIFILM Cellular Dynamics, Inc Sygnature Discovery BPS Bioscience Inc. Iambic Therapeutics Carmot Therapeutics, Inc. Active Motif The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology Structure Therapeutics   Antheia, Inc. Anima Biotech Genesis Therapeutics Reaction Biology Kallyope Ligand Pharmaceuticals      Remix Therapeutics o2h discovery NETZSCH Premier Technologies, LLC   Terray Therapeutics  Seismic Therapeutic Charnwood Discovery Flare Therapeutics Kumquat Biosciences Inc.      Plexium ACEA Biosciences AnaSpec Zephyr AI    Eurofins DiscoverX  Neomorph, Inc. Calibr-Skaggs Institute for Innovative Medicines      GemPharmatech MBL International Corporation   Neuron23 Cajal Neuroscience   Belharra Therapeutics

Drug Discovery Market Set for Rapid Growth: $41.3 Billion by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dkur5VbB The global #drugdiscovery services market is on a rapid growth trajectory, estimated to reach an impressive $41.3 billion by 2028! 🎉 This significant growth, at a CAGR of 14.9% from 2023 to 2028, demonstrates the increasing demand for advanced drug discovery services. X-Chem, Inc. Quantori NanoCellect Biomedical, Inc. FUJIFILM Cellular Dynamics, Inc. Iambic Therapeutics Sygnature Discovery XtalPi Inc. Skyhawk Therapeutics BPS Bioscience Inc. Biocytogen Anima Biotech The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology Active Motif Reaction Biology Kallyope NETZSCH Premier Technologies, LLC o2h discovery Structure Therapeutics Terray Therapeutics Remix Therapeutics Eureka Therapeutics, Inc. Neomorph, Inc. Charnwood Discovery ACEA Biosciences Plexium AnaSpec Eurofins DiscoverX HTG Molecular Diagnostics Calibr-Skaggs Institute for Innovative Medicines MBL International Corporation GemPharmatech Belharra Therapeutics HotSpot Therapeutics, Inc. Neuron23 Jubilant Biosys Limited Cajal Neuroscience NanoImaging Services Skills Alliance abcam BenevolentAI

Drug Discovery Services Market Latest Statistics 2024 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dtcN7Umn The size of global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028 Companies From the Market Collaborative Drug Discovery - CDD Vault    Alzheimer's Drug Discovery Foundation    Dalriada Drug Discovery Drug Hunter Warren Center for Neuroscience Drug Discovery 23andMe MEDGENOME Exelixis Recursion Blueprint Medicines Phenomenex GeneDx Relay Therapeutics insitro Luminex Gilson D. E. Shaw Research Eikon Therapeutics Atomwise Ventana Medical Systems Alector Frontier Medicines GenScript ProBio Sanford Burnham Prebys Nimbus Therapeutics Vizgen ATCC Invicro Cellarity Rapport Therapeutics Ventus Therapeutics Genesis Biotechnology Group iBio, Inc. Valo Health MOMA Therapeutics Dewpoint Therapeutics  Southern Research Covaris Coriell Institute for Medical Research  Skyhawk Therapeutics

Will the Global Cell Therapy Technologies Market Reach $7.8 Billion by 2028 with a CAGR of 13.3%? 𝐔𝐧𝐥𝐨𝐜𝐤 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 | 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dnyXKdhb The global cell therapy technologies market, valued at approximately $4.2 billion in 2023, is poised to expand to $7.8 billion by 2028, achieving a compound annual growth rate (CAGR) of 13.3% during the forecast period. Key players shaping this market include Thermo Fisher Scientific, Merck KGaA, Darmstadt, Germany, Danaher Corporation, BD, Lonza, and Sartorius. These companies drive innovation in cell therapy technology, contributing to advancements in regenerative medicine and biotechnology. Factors driving market growth include increasing investment in biotechnology research, rising prevalence of chronic diseases, and advancements in cell-based therapies worldwide. #CellTherapy #RegenerativeMedicine #Biotechnology #HealthcareInnovation #MedicalResearch #GlobalHealth #Biotech #StemCells #CancerTreatment #CellularTherapy #ThermoFisherScientific #MerckKGaA #DanaherCorporation #BD #LonzaGroup #SartoriusAG #MarketResearch #HealthcareTrends #HealthcareIndustry #MarketForecast #HealthTech #MedicalEquipment #Biopharma #DrugDevelopment #HealthcareInvestment #MedicalTechnology #GlobalMarket #MarketGrowth #HealthcareServices #HealthcareProviders #DigitalHealth #PrecisionMedicine #PersonalizedMedicine #HealthcareCosts #HealthcareAccessibility #HealthcareEcosystem #EmergingMarkets #PublicHealth #HealthcarePolicy #HealthcareQuality #HealthcareManagement #HealthcareStartups #HealthcareProfessionals #HealthcareStrategy #HealthcareChallenges #HealthcareSustainability #HealthcareLeadership #HealthcareEducation #HealthcareAwareness #HealthcareImpact #HealthcareDisruption #HealthcareFuture #HealthcareEquality #HealthcareEquity #HealthcareWorkforce #GlobalHealthcare #HealthcareCollaboration #HealthcarePartnerships #HealthcareAdvancements #HealthcareGoals #HealthcareVision #MedicalTraining #MedicalResearch #Bioengineering #BiomedicalResearch #BiomedicalEngineering #CellTherapyTechnologies #TherapeuticCells #TissueEngineering #LifeSciences #Bioprocessing #CellCulture #GeneTherapy #Immunotherapy #CellBasedTherapy #DrugDiscovery #ClinicalTrials #HealthcareSystems #DigitalTransformation #BiotechIndustry #HealthcareTech

Drug Discovery Services Market Latest Statistics 2024 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dtcN7Umn The size of global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028 Companies From the Market HotSpot Therapeutics, Inc.   NanoImaging Services   Hamilton Storage Sartorius Jubilant Biosys Limited BioXcel, LLC Evotec NuChem Sciences - Sygnature Discovery North America  Enko® abcam BenevolentAI Exscientia Eurofins Advinus  Selleck Chemicals LLC     CNIO - Spanish National Cancer Research Centre      CENTOGENE   Premas Biotech Ridgeline Discovery Biotage Isomorphic Labs Xaira Therapeutics  Pioneering Medicines  JSS Medical Research SPT Labtech Selvita TandemAI bit.bio Enable Medicine Ontario Institute for Cancer Research      Healx   Experimental Drug Development Centre (EDDC) Gubra Xenon Pharmaceuticals Inc. Aurigene Oncology Limited   OSE Immunotherapeutics      Enterome Ncardia IRBM Nanolive SA  AQEMIA 

From $𝟒.𝟐 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐭𝐨 $𝟕.𝟖 𝐁𝐢𝐥𝐥𝐢𝐨𝐧: Rapid Expansion of the 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 Market through 𝟐𝟎𝟐𝟖 𝐔𝐧𝐥𝐨𝐜𝐤 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 | 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dnyXKdhb The global cell therapy technologies market was valued at approximately $4.2 billion in 2023 and is projected to grow to $7.8 billion by 2028, achieving a compound annual growth rate (CAGR) of 13.3% during this period. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Thermo Fisher Scientific (US), Merck KGaA, Darmstadt, Germany (Germany), Danaher Corporation (US), BD (US), 𝐋𝐨𝐧𝐳𝐚 𝐆𝐫𝐨𝐮𝐩 (Switzerland), Sartorius AG (Germany). 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐬𝐞𝐜𝐭𝐨𝐫 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 𝐚𝐫𝐞: Gamida Cell Ltd. Kite Pharma  AGC Biologics BlueRock Therapeutics Poseida Therapeutics, Inc. Iovance Biotherapeutics, Inc. FUJIFILM Irvine Scientific  Arsenal Biosciences, Inc. Lyell Immunopharma Center for Breakthrough Medicines GenScript ProBio CARGO Therapeutics Sorrento Therapeutics, Inc. Arcellx Parse Biosciences Vericel® Corporation Sonoma Biotherapeutics Carisma Therapeutics A2 Biotherapeutics, Inc. Cognate BioServices, a Charles River Company Nkarta, Inc. Capricor Therapeutics, Inc. Affini-T Therapeutics Adicet Bio, Inc Artiva Biotherapeutics FUJIFILM Cellular Dynamics, Inc Shoreline Biosciences, Inc. Cellipont Bioservices PBS Biotech Paragon Bioservices, Inc. Neurona Therapeutics    Genezen BioCentriq PeproTech Adaptimmune 𝐂𝐓𝐌𝐂 / 𝐀 𝐣𝐨𝐢𝐧𝐭 𝐯𝐞𝐧𝐭𝐮𝐫𝐞 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝐑𝐞𝐬𝐢𝐥𝐢𝐞𝐧𝐜𝐞 + 𝐌𝐃 𝐀𝐧𝐝𝐞𝐫𝐬𝐨𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐞𝐧𝐭𝐞𝐫    𝐏𝐫𝐨𝐊𝐢𝐝𝐧𝐞𝐲 𝐂𝐨𝐫𝐩.    𝐂𝐂𝐑𝐌    𝐓𝐞𝐬𝐬𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐋𝐭𝐝    𝐛𝐢𝐭.𝐛𝐢𝐨    𝐐𝐮𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬    𝐎𝐮𝐭𝐩𝐚𝐜𝐞 𝐁𝐢𝐨    𝐑𝐄𝐆𝐑𝐎𝐖 𝐁𝐈𝐎𝐒𝐂𝐈𝐄𝐍𝐂𝐄𝐒    𝐑𝐨𝐬𝐥𝐢𝐧𝐂𝐓    𝐆𝐂 𝐂𝐞𝐥𝐥    𝐑𝐞𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬    𝐓𝐂 𝐁𝐢𝐨𝐏𝐡𝐚𝐫𝐦     𝐇𝐞𝐦𝐚𝐂𝐚𝐫𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐢𝐨𝐧, 𝐚 𝐂𝐡𝐚𝐫𝐥𝐞𝐬 𝐑𝐢𝐯𝐞𝐫 𝐂𝐨𝐦𝐩𝐚𝐧𝐲    𝐂𝐲𝐭𝐨𝐧𝐨𝐦𝐞    𝐁𝐨𝐧𝐮𝐬 𝐁𝐢𝐨𝐠𝐫𝐨𝐮𝐩   #CellTherapy #Biotechnology #HealthInnovation #MedicalResearch #GeneTherapy #Pharmaceuticals #Healthcare #LifeSciences #RegenerativeMedicine #StemCells #ClinicalTrials #CAGRGrowth #HealthTech #Biopharma #PatientCare #Immunotherapy #Biologics #DrugDevelopment #MedicalTechnology #CancerResearch #HealthOutcomes #PrecisionMedicine #Laboratory #HealthcareSolutions #HealthInvestment #BiotechIndustry #HealthEducation #DigitalHealth #PatientSafety #LaboratoryResearch #InnovationInHealthcare #HealthcareTrends #Therapeutics #CellularTherapies #HealthcareIT #MedicalDevices #ClinicalResearch #HealthEconomics #Microfluidics #DrugDiscovery #PharmaTrends #HealthcareGrowth #FutureOfHealthcare #ResearchInnovation #PatientEngagement

Check out the latest report from IMIR Market Research Pvt. Ltd.  on the 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝗷𝘂𝗴𝗮𝘁𝗲𝘀 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2028 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Condition (Myeloma, Lymphoma, Breast Cancer, Others (Urothelial Cancer)), By Linker (Cleavable Linker, Non-cleavable Linker), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031. 📚 𝐆𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞:👇 https://lnkd.in/gy2CqEuu 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞::👇 AbbVie. ADC Therapeutics AstraZeneca Aurigene Pharmaceutical Services Limited. Axplora BioTechnique Boehringer Ingelheim Cambrex Catalent Pharma Solutions. Cerbios-Pharma SA Corden Pharma - A Full-Service CDMO Creative Biolabs Cyano Biotech is now Simris Biologics Daiichi Sankyo, Inc. EirGenix, Inc. GBI Bio Gilead Sciences GTP Bioways ImmunoGen, Inc. Lonza MabPlex International Co., Ltd. Merck KGaA, Darmstadt, Germany Mersana Therapeutics MicroBiopharm Japan Co., Ltd. Novasep Pfizer. Pierre Fabre Group Piramal Pharma Solutions Recipharm Regeneron Pharmaceuticals, Inc. Samsung Biologics Sanofi Sartorius Siegfried SK pharmteco Sterling Pharma Solutions Thermo Fisher Scientific WuXi Biologics WuXi STA, a subsidiary of WuXi AppTec #conference #antibodydrugconjugates #hpapi #marketsandmarkets #oncologydrugs #pharmaceuticals #hightpotentmedicines #highpotentmedicines #milan #molecularbiology #chemicals #cancer #drug #antibdody #researchers #costeffective #technology #medchemexpress #biochemicals #biotechnolabs #immunology #hpmcboston #biotechnology #biology #celltherapy #medicine #science #health #research #cellbiology

🔗 Site-specific vs. Stochastic Conjugation in ADC Development🔗 Early-generation #ADCs often relied on #stochastic #conjugation methods, but the choice of conjugation strategy has a critical impact on drug efficacy and safety. One of the key drawbacks of stochastic conjugation is its instability, which can lead to premature payload release, increasing the risk of off-target toxicity as the cytotoxic payload may be released before reaching its intended target. 💡 Site-specific conjugation (#SSC) has emerged as an alternative, offering greater precision and control. While SSC still represents a small portion of approved ADCs, its adoption is growing rapidly. With clear advantages, SSC is expected to dominate ADC development in the near future. Examples of site-specific conjugation methods, their 3-year compound annual growth rates (CAGR), and corresponding conjugation techniques include: -           #AbClick® Pro (AbTis Co.,Ltd.) – 91% CARG - Click -           #GeminiMab™ (Syndivia ) – 82% CARG – Disulphide Bridging -           #iLDC® (GeneQuantum Healthcare (Suzhou) Co., Ltd ) – 33% CARG – Enzymatic -           #GlycoConnect™ (Synaffix BV) – 34% CARG - Click -           #ConjuAll™ (Ligachem) – 19% CARG – Enzymatic ⚙️ LigaChem’s ConjuAll™ conjugation technology stands out as the most widely adopted, with 44 molecules utilizing it. A few clinically validated examples include: -           Caxmotabart entudotin - Iksuda Therapeutics, LigaChem, Fosun Pharma – Phase 3 -           LCB84 - Janssen Biotech, Inc., LigaChem, Mediterranea-theranostic – Phase 1/2 -           CS5001 – ABL Bio, LigaChem, CStone Pharmaceuticals – Phase 1 -           IKS03 - Iksuda Therapeutics, LigaChem, Light Chain Bioscience | Novimmune SA – Phase 1 Some preclinical molecules using LigaChem’s ConjuAll™ conjugation technology: -           YBL-001 - Pyxis Oncology, Y-Biologics, LigaChem -           GT-00X ADC – Glycotope, LigaChem -           LCB42A – Amgen, LigaChem Big thanks to Callum Angus for presenting this data on behalf of Hanson Wade Intelligence and Beacon at a recent ADC webinar, sample of slides can be found here: https://lnkd.in/ew_brSzW 📊 Below is a visualization of the YoY growth of ADCs using SSC vs. Stochastic Conjugation 👇 #ADCDevelopment #BiotechInnovation #SiteSpecificConjugation #Pharmaceuticals #DrugDevelopment #Biopharma #AntibodyDrugConjugates

Exosome Research Market | Grows at CAGR of 16.0% by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://lnkd.in/d7xn3yke The global exosome research market in terms of revenue was estimated to be worth $169 million in 2023 and is poised to reach $356 million by 2028, growing at a CAGR of 16.0% from 2023 to 2028. Coya Therapeutics, Inc. Curexsys GmbH EV Therapeutics ILIAS Biologics Inc. Rion Aesthetics SHIFTBIO INC. Mantra Bio. Sphere Fluidics Limited Mursla Bio Exopharm Ltd Aruna Bio, Inc. Lineage Cell Therapeutics EXOCEL BIO Xosomix CODIAK Exosome Diagnostics VivaZome Therapeutics Avalon Globocare Corp (NASDAQ: ALBT) VITTI LABS Diadem Biotherapeutics EXOKĒRYX Florica Therapeutics VesiCURE Therapeutics Tymora Analytical Operations Aegle Therapeutics Aethlon Medical, Inc. Anjarium Biosciences Aruna Bio, Inc. Capricor Therapeutics, Inc. Ciloa SAS Creative Medical Technologies Inc Direct Biologics EVerZom

The first day of Biologics US 2024 is filled with industry insights and engaging sessions that you won't want to miss! Whether you're interested in antibody discovery or the latest advancements in NextGen therapeutics, we have something for you. Day One Tracks: 1️⃣ Antibody Discovery, Engineering & Analysis 2️⃣ Novel NextGen Therapeutics - Multispecifics, Cell Engagers, & Other New Modalities 3️⃣ Engineering Conjugates to Enhance Therapeutic Potential 4️⃣ Advancing Analytical Methods 5️⃣ Peptide Discovery & Development Connect with Industry Experts in Our Interactive Sessions: ⭐ Accelerating Antibody Discovery ⭐ Towards Rational Computational Peptide Design ⭐ ADC Target Selection ft. experts from Pfizer, Bristol Myers Squibb, Proteogenomics Research Institute for Systems Medicine (PRISM), Avidity Biosciences, Inc. & C4 Therapeutics, Inc. Check out the full agenda here! ➡️ https://hubs.la/Q02JJGFv0 #OGBiologics #BiologicsUS2024 #Innovation #AntibodyDiscovery #PeptideDevelopment